Matches in SemOpenAlex for { <https://semopenalex.org/work/W4291020174> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W4291020174 endingPage "3810" @default.
- W4291020174 startingPage "3800" @default.
- W4291020174 abstract "Favipiravir and Meropenem have been concurrently used as directly acting antiviral and antibiotic agents for the treatment of coronavirus disease in human plasma. Accurate and specific reversed phase ultra‐performance liquid chromatographic and high‐performance thin‐layer chromatographic methods were developed and validated for the first time analysis of this combination in spiked human plasma using Cefepime as an internal standard. In the developed ultra‐high‐performance liquid chromatography method, separation was performed on a BEH C18 column with a mixture of ACN and 0.05 M potassium dihydrogen orthophosphate (pH = 3) in a ratio of 10:90 (v/v) as an eluate. Scanning of the separated peaks was at 298 nm. The developed method showed high sensitivity, and the drugs showed linearity in the range of 5–70 μg/ml for Favipiravir and 2–50 μg/ml for Meropenem. The proposed high‐performance thin‐layer chromatographic method included the separation using a mixture of ethyl acetate:methanol:deionized water:formic acid (5:4:1.5:0.3, by volume), then spots detection at 300 nm. Methods were investigated for greenness using the eco‐scale and national environmental method index tools and were validated according to food and drug administration guidelines. Methods can be applied for bio‐analysis and therapeutic drug monitoring studies." @default.
- W4291020174 created "2022-08-13" @default.
- W4291020174 creator A5015075555 @default.
- W4291020174 creator A5033683744 @default.
- W4291020174 creator A5044629509 @default.
- W4291020174 creator A5046475222 @default.
- W4291020174 creator A5074199404 @default.
- W4291020174 date "2022-08-19" @default.
- W4291020174 modified "2023-09-26" @default.
- W4291020174 title "Sensitive and selective bioscreening of the most commonly used coronavirus disease drug, Favipiravir, and its co‐administered therapeutic, Meropenem, in human plasma" @default.
- W4291020174 cites W1503376607 @default.
- W4291020174 cites W1967407061 @default.
- W4291020174 cites W1980654095 @default.
- W4291020174 cites W1999519460 @default.
- W4291020174 cites W2002784611 @default.
- W4291020174 cites W2111033110 @default.
- W4291020174 cites W2111092491 @default.
- W4291020174 cites W2112161950 @default.
- W4291020174 cites W2137785177 @default.
- W4291020174 cites W2547224784 @default.
- W4291020174 cites W3014356995 @default.
- W4291020174 cites W3021567865 @default.
- W4291020174 cites W3023977941 @default.
- W4291020174 cites W3085071740 @default.
- W4291020174 cites W3107624489 @default.
- W4291020174 cites W3117027375 @default.
- W4291020174 cites W3137536162 @default.
- W4291020174 cites W4220766084 @default.
- W4291020174 cites W4226552977 @default.
- W4291020174 cites W4280560879 @default.
- W4291020174 doi "https://doi.org/10.1002/jssc.202200332" @default.
- W4291020174 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35948316" @default.
- W4291020174 hasPublicationYear "2022" @default.
- W4291020174 type Work @default.
- W4291020174 citedByCount "1" @default.
- W4291020174 countsByYear W42910201742023 @default.
- W4291020174 crossrefType "journal-article" @default.
- W4291020174 hasAuthorship W4291020174A5015075555 @default.
- W4291020174 hasAuthorship W4291020174A5033683744 @default.
- W4291020174 hasAuthorship W4291020174A5044629509 @default.
- W4291020174 hasAuthorship W4291020174A5046475222 @default.
- W4291020174 hasAuthorship W4291020174A5074199404 @default.
- W4291020174 hasConcept C112705442 @default.
- W4291020174 hasConcept C179998833 @default.
- W4291020174 hasConcept C185592680 @default.
- W4291020174 hasConcept C2777050379 @default.
- W4291020174 hasConcept C2777379063 @default.
- W4291020174 hasConcept C2779375183 @default.
- W4291020174 hasConcept C2779631663 @default.
- W4291020174 hasConcept C2780272996 @default.
- W4291020174 hasConcept C43617362 @default.
- W4291020174 hasConcept C501593827 @default.
- W4291020174 hasConcept C55493867 @default.
- W4291020174 hasConcept C71924100 @default.
- W4291020174 hasConcept C94665300 @default.
- W4291020174 hasConcept C98274493 @default.
- W4291020174 hasConceptScore W4291020174C112705442 @default.
- W4291020174 hasConceptScore W4291020174C179998833 @default.
- W4291020174 hasConceptScore W4291020174C185592680 @default.
- W4291020174 hasConceptScore W4291020174C2777050379 @default.
- W4291020174 hasConceptScore W4291020174C2777379063 @default.
- W4291020174 hasConceptScore W4291020174C2779375183 @default.
- W4291020174 hasConceptScore W4291020174C2779631663 @default.
- W4291020174 hasConceptScore W4291020174C2780272996 @default.
- W4291020174 hasConceptScore W4291020174C43617362 @default.
- W4291020174 hasConceptScore W4291020174C501593827 @default.
- W4291020174 hasConceptScore W4291020174C55493867 @default.
- W4291020174 hasConceptScore W4291020174C71924100 @default.
- W4291020174 hasConceptScore W4291020174C94665300 @default.
- W4291020174 hasConceptScore W4291020174C98274493 @default.
- W4291020174 hasIssue "20" @default.
- W4291020174 hasLocation W42910201741 @default.
- W4291020174 hasLocation W42910201742 @default.
- W4291020174 hasOpenAccess W4291020174 @default.
- W4291020174 hasPrimaryLocation W42910201741 @default.
- W4291020174 hasRelatedWork W1972377682 @default.
- W4291020174 hasRelatedWork W2013924808 @default.
- W4291020174 hasRelatedWork W2077423873 @default.
- W4291020174 hasRelatedWork W2079699236 @default.
- W4291020174 hasRelatedWork W2093917715 @default.
- W4291020174 hasRelatedWork W2111667493 @default.
- W4291020174 hasRelatedWork W2161957616 @default.
- W4291020174 hasRelatedWork W2241812387 @default.
- W4291020174 hasRelatedWork W2357111774 @default.
- W4291020174 hasRelatedWork W2474278154 @default.
- W4291020174 hasVolume "45" @default.
- W4291020174 isParatext "false" @default.
- W4291020174 isRetracted "false" @default.
- W4291020174 workType "article" @default.